Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research report report published on Friday morning, Benzinga reports. HC Wainwright currently has a $75.00 target price on the stock.

Aligos Therapeutics Price Performance

Shares of NASDAQ:ALGS opened at $9.14 on Friday. The firm has a market capitalization of $713.93 million, a price-to-earnings ratio of -7.14 and a beta of 2.18. The business’s 50 day moving average price is $13.19 and its 200-day moving average price is $16.31. Aligos Therapeutics has a 1 year low of $8.70 and a 1 year high of $30.00.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, topping the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The company had revenue of $1.06 million during the quarter. During the same quarter last year, the firm posted ($10.75) earnings per share. On average, sell-side analysts expect that Aligos Therapeutics will post -8.15 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Armistice Capital LLC raised its holdings in Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after acquiring an additional 363,000 shares during the last quarter. Altitude Crest Partners Inc. acquired a new stake in shares of Aligos Therapeutics in the fourth quarter valued at approximately $1,889,000. Opaleye Management Inc. increased its holdings in shares of Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after purchasing an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in Aligos Therapeutics by 26.1% during the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after buying an additional 171,490 shares in the last quarter. 60.43% of the stock is owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).